Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies

Microbial Pathogenesis

Volumn 66, Issue , 2014, Pages 14-23

  Dinesh, Neeradi ^a   Pallerla, Dheeraj Sree Ram ^a   Kaur, Preet Kamal ^a   Kishore Babu, Neerupudi ^a   Singh, Sushma ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cholesterol; Ergosterol; HMGR; Leishmania donovani; Statins

Indexed keywords

ATORVASTATIN; ERGOSTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESVERATROL; SIMVASTATIN;

ALPHA HELIX; ARTICLE; BINDING AFFINITY; BIOPHYSICS; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; ENZYME DENATURATION; ENZYME INHIBITION; ENZYME STABILITY; ENZYME STRUCTURE; GENETIC CODE; GENOME ANALYSIS; GROWTH INHIBITION; GROWTH RATE; HMGR GENE; IC 50; LEISHMANIA DONOVANI; NONHUMAN; OPEN READING FRAME; PH MEASUREMENT; PRIORITY JOURNAL; PROMASTIGOTE; SIGNAL TRANSDUCTION; STOICHIOMETRY;

LEISHMANIA DONOVANI; RATTUS;

CHOLESTEROL; ERGOSTEROL; HMGR; LEISHMANIA DONOVANI; STATINS;

AMINO ACID SEQUENCE; CHOLESTEROL; CLONING, MOLECULAR; DNA, PROTOZOAN; DRUG DELIVERY SYSTEMS; ERGOSTEROL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, PROTOZOAN; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEISHMANIA DONOVANI; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PROTEIN STRUCTURE, SECONDARY; PYRROLES; RECOMBINANT PROTEINS; SEQUENCE ANALYSIS, DNA; SIMVASTATIN; STILBENES;

EID: 84889650341     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2013.11.001     Document Type: Article

References (60)

1. Berman J. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol 2008, 4:1209-1216.
2. Urbina J.A. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997, 114(Suppl.1):S91-S99.
3. Roberts C.W., McLeod R., Rice D.W., Ginger R., Chance M.L., Goad L.J. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 2003, 126:129-142.
4. Jimenez-Jimenez C., Carrero-Lerida J., Sealey-Cardona M., Ruiz Perez L.M., Urbina J.A., Gonzalez Pacanowska D. Delta24(25)-sterol methenyltransferase: intracellular localization and azasterol sensitivity in Leishmania major promastigotes overexpressing the enzyme. Mol Biochem Parasitol 2008, 160:52-59.
5. Goad L.J., Holz G.G., Beach D.H. Sterols of ketoconazole-inhibited Leishmania mexicana mexicana promastigotes. Mol Biochem Parasitol 1985, 15:257-279.
6. Friesen J.A., Rodwell V.W. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol 2004, 5:248-255.
7. Trocha P.J., Sprinson D.B. Location and regulation of early enzymes of sterol biosynthesis in yeast. Arch Biochem Biophys 1976, 174:45-51.
8. Pena-Diaz J., Montalvetti A., Flores C.L., Constan A., Hurtado-Guerrero R., De Souza W., et al. Mitochondrial localization of the mevalonate pathway enzyme 3-Hydroxy-3-methyl-glutaryl-CoA reductase in the trypanosomatidae. Mol Biol Cell 2004, 15:1356-1363.
9. Wanderley D.S., Rodrigues J.C.F. Sterol biosynthesis pathway as target for anti-trypanosomatid drugs. Interdiscip Perspect Infect Dis 2009, 2009:1-19.
10. Caelles C., Ferrer A., Balcells L., Hegardt G., Boronat A. Isolation and structural characterization of a cDNA encoding Arabidopsis thaliana 3-hydroxy-3-methylglutaryl coenzyme A reductase. Plant Mol Biol 1989, 13:627-638.
11. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
12. Maltese W.A. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990, 4:3319-3328.
13. Hedl M., Rodwell V.W. Inhibition of the class II HMG-CoA reductase of Pseudomonas mevalonii. Protein Sci 2004, 13:1693-1697.
14. Kim D.Y., Stauffacher C.V., Rodwell V.W. Dual coenzyme specificity of Archaeoglobus fulgidus HMG-CoA reductase. Protein Sci 2000, 9:1226-1234.
15. Wilding E.I., Kim D.Y., Bryant A.P., Gwynn M.N., Lunsford R.D., McDevitt D., et al. Essentiality, expression, and characterization of the class II 3-hydroxy-3-methylglutaryl coenzyme A reductase of Staphylococcus aureus. JBacteriol 2000, 180:5147-5152.
16. Hedl M., Sutherlin A., Wilding E.I., Mazzulla M., McDevitt D., Lane P., et al. Enterococcus faecalis acetoacetyl-coenzyme A thiolase/3-hydroxy-3-methylglutaryl-coenzyme A reductase, a dual-function protein of isopentenyl diphosphate biosynthesis. JBacteriol 2002, 184:2116-2122.
17. Takahashi S., Kuzuyama T., Seto H. Purification, characterization, and cloning of a eubacterial 3-hydroxy-3-methylglutaryl coenzyme A reductase, a key enzyme involved in biosynthesis of terpenoids. JBacteriol 1999, 181:1256-1263.
18. Istvan E.S., Palnitkar M., Buchanan S.K., Deisenhofer J. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J 2000, 19:819-830.
19. Montalvetti A., Pena-Diaz J., Hurtado R., Ruiz-Perez L.M., Gonzalez-Pacanowska D. Characterization and regulation of Leishmania major 3-hydroxy-3-methylglutaryl-CoA reductase. Biochem J 2000, 349:27-34.
20. Pena-Diaz J., Montalvetti A., Camacho A., Gallego C., Ruiz-Perez L.M., Gonzalez-Pacanowska D. Asoluble 3-hydroxy-3-methylglutaryl-CoA reductase in the protozoan Trypanosoma cruzi. Biochem J 1997, 324:619-626.
21. Ryder N.S. Mechanism of action and biochemical selectivity of allylamine antimycotic agents. Ann N Y Acad Sci 1988, 544:208-220.
22. Troke P.F., Marriott M.S., Richardson K., Tarbit M.H. Invitro potency and invivo activity of azoles. Ann N Y Acad Sci 1988, 544:284-293.
23. Urbina J.A., Concepcion J.L., Caldera A., Payares G., Sanoja C., Otomo T., et al. Invitro and invivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents 2004, 48:2379-2387.
24. Parquet V., Briolant S., Torrentino-Madamet M., Henry, Almeras L., Amalvict R., et al. Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Antimicrob Agents 2009, 53:2248-2252.
25. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292:1160-1164.
26. Arguelles N., Sanchez-Sandoval E., Mendieta A., Villa-Tanaca L., Garduno-Siciliano L., Jimenez F., et al. Design, synthesis, and docking of highly hypolipidemic agents: Schizosaccharomyces pombe as a new model for evaluating alpha-asarone-based HMG-CoA reductase inhibitors. Bioorg Med Chem 2010, 18:4238-4248.
27. Tabernero L., Rodwell V.W., Stauffacher C.V. Crystal structure of a statin bound to a class II hydroxymethylglutaryl-CoA reductase. JBiol Chem 2003, 278:19933-19938.
28. Botelho-Nevers E., Espinosa L., Raoult D., Rolain J.M. Lovastatin, but not pravastatin, limits invitro infection due to Coxiella burnetii. JAntimicrob Chemother 2008, 62:845-847.
29. Kessler R.L., Soares M.J., Probst C.M., Krieger M.A. Trypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell death. PLoS One 2013, 8:1-16.
30. Ginger M.L., Chance M.L., Sadler I.H., Goad L.J. The biosynthetic incorporation of the intact leucine skeleton into sterol by the trypanosomatid Leishmania Mexicana. JBiol Chem 2001, 276:11674-11682.
31. Garcia-Pelayo M.C., Garcia-Peregrin E., Martinez-Cayuela M. Differential translational effects of myristic acid and eicosapentaenoic acid on 3-hydroxy-3-methylglutaryl-CoA reductase from Reuber H35 hepatoma cells. Exp Biol Med 2004, 229:781-786.
32. Hurtado G.R., Pena D.J., Montalvetti A., Ruiz P.L.M., Gonzalez P.D. Kinetic properties and inhibition of Trypanosoma cruzi 3-hydroxy-3-methylglutaryl CoA reductase. FEBS Lett 2002, 510:141-144.
33. Padmanabhan P.K., Mukherjee A., Singh S., Chattopadhyaya S., Gowri V.S., Myler P.J., et al. Glyoxalase I from Leishmania donovani: a potential target for anti-parasite drug. Biochem Biophys Res Commun 2005, 337:1237-1248.
34. Rai S., Dwivedi U.N., Goyal N. Leishmania donovani trypanothione reductase: role of urea and guanidine hydrochloride in modulation of functional and structural properties. Biochim Biophys Acta 2009, 1794:1474-1484.
35. Singh T.S., Mitra S. Interaction of cinnamic acid derivatives with serum albumins: a fluorescence spectroscopic study. Spectrochim Acta A Mol Biomol Spectrosc 2011, 78:942-948.
36. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. JImmunol Methods 1983, 65:55-63.
37. Shang C.H., Zhu F., Li N., Ou-Yang X., Shi L., Zhao M.W., et al. Cloning and characterization of a gene encoding HMG-CoA reductase from Ganoderma lucidum and its functional identification in yeast. Biosci Biotech Biochem 2008, 72:1333-1339.
38. Coppens I., Bastin P., Levade T., Courtoy P.J. Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Trypanosoma brucei. Mol Biochem Parasitol 1995, 69:29-40.
39. Pracht D., Elm C., Gerber J., Bergmann S., Rohde M., Seiler M., et al. PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. Infect Immun 2005, 73:2680-2689.
40. Heuston S., Begley M., Davey M.S., Eberl M., Casey P.G., Hill C., et al. HmgR, a key enzyme in the mevalonate pathway for isoprenoid biosynthesis, is essential for growth of Listeria monocytogenes EGDe. Microbiology 2012, 158:1684-1693.
41. Bochar D.A., Brown J.R., FDoolittle W., Klenk H.P., Lam W., Schenk M.E., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase of Sulfolobus solfataricus: DNA sequence, phylogeny, expression in Escherichia coli of the hmgA gene, and purification and kinetic characterization of the gene product. JBacteriol 1997, 179:3632-3638.
42. Jordan-Starck T.C., Rodwell V.W. Pseudomonas mevalonii 3-hydroxy-3-methylglutaryl-CoA reductase. Characterization and chemical modification. JBiol Chem 1989, 264:17913-17918.
43. Mayer R.J., Debouck C., Metcalf B.W. Purification and properties of the catalytic domain of human 3-hydroxy-3-methylglutaryl-CoA reductase expressed in Escherichia coli. Arch Biochem Biophys 1988, 267:110-118.
44. Chattopadhyay A., Rawat S.S., Kelkar D.A., Ray S., Chakrabarti A. Organization and dynamics of tryptophan residues in erythroid spectrin: novel structural features of denatured spectrin revealed by the wavelength-selective fluorescence approach. Protein Sci 2003, 12:2389-2403.
45. Hu Y.J., Liu Yi, Shen X.S., Fang X.Y., Qu S.S. Studies on the interaction between 1-hexylcarbamoyl-5-fluorouracil and bovine serum albumin. JMol Struct 2005, 738:143-147.
46. Pak V.V., Koo M., Kim M.J., Yun L., Kwon D.Y. Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem 2008, 16:1309-1318.
47. Barrow C.J., Yasuda A., Kenny P.T., Zagorski M.G. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. JMol Biol 1992, 225:1075-1093.
48. Istvan E.S. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J 2002, 144:S27-S32.
49. Kedzierski L., Curtis J.M., Kaminska M., Jodynis-Liebert J., Murias M. Invitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes. Parasitol Res 2007, 102:91-97.
50. Andrade Neto V.V., Cicco N.N., Cunha Junior E.F., Canto Cavalheiro M.M., Atella G.C., Torres-Santos E.C. The pharmacological inhibition of sterol biosynthesis in Leishmania is counteracted by enhancement of LDL endocytosis. Acta Trop 2011, 119:194-198.
51. Liu H., Wang Z., Li Y., Li W., Chen Y. Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma invitro and invivo. Neoplasma 2013, 60:240-246.
52. Pradines B., Torrentino-Madamet M., Fontaine A., Henry M., Baret E., Mosnier J., et al. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob Agents Chemother 2007, 51:2654-2655.
53. Parquet V., Henry M., Wurtz N., Dormoi J., Briolant S., Gil M., et al. Atorvastatin as a potential anti-malarial drug: invitro synergy in combinational therapy with quinine against Plasmodium falciparum. Malar J 2010, 9:139.
54. Lucas I.K., Kolodziej H. Invitro antileishmanial activity of resveratrol originates from its cytotoxic potential against host cells. Planta Med 2012, 79:20-26.
55. Vaquero M., Caballero R., Gomez R., Nunez L., Tamargo J., Delpon E. Effects of atorvastatin and simvastatin on atrial plateau currents. JMol Cell Cardiol 2007, 42:931-945.
56. Singh C.K., Kumar A., Hitchcock D.B., Fan D., Goodwin R., LaVoie H.A., et al. Resveratrol prevents embryonic oxidative stress and apoptosis associated with diabetic embryopathy and improves glucose and lipid profile of diabetic dam. Mol Nutr Food Res 2011, 55:1186-1196.
57. Perchellet J.P., Perchellet E.M., Crow K.R., Buszek K.R., Brown N., Ellappan S., et al. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. Int J Mol Med 2009, 24:633-643.
58. Westermeyer C., Macreadie I.G. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res 2007, 7:436-441.
59. Haughan P.A., Chance M.L., Goad L.J. Effects of an azasterol inhibitor of sterol 24-transmethylation on sterol biosynthesis and growth of Leishmania donovani promastigotes. Biochem J 1995, 308:31-38.
60. Yeagle P.L. Lanosterol and cholesterol have different effects on phospholipid acyl chain ordering. Biochim Biophys Acta 1985, 815:33-36.